Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.
Last week, UK biotechnology firm Oxford Cannabinoid Technologies (OCT), one of the first cannabis companies in history to list on the London Stock Exchange (LSE), informed investors of its intention to leave.
Synbiotic [stock_market_widget type=”chart” template=”line” assets=”SBX.DE” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] German cannabis group SynBiotic has capitalised on the recent explosion in medical cannabis patients since the country’s landmark CanG came into effect last month.
MGC Pharmaceuticals / Argent BioPharma [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals has become the latest UK-listed cannabis company to opt for a rebrand in 2024, as businesses increasingly try to diversify and distance themselves from the difficulties experienced across the cannabis sector over the last year…
This week, British pharmaceutical cannabis firm Oxford Cannabinoid Technologies (OCT) announced that the ‘final dose’ in its crucial Phase I clinical trial had been administered, with no ‘drug adverse effects observed’.
Akanda Akanda unveiled its unaudited financial figures for the six months to the end of June 2022, two weeks after revealing that its CEO has been on ‘paid leave of absence’ since November.
Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies (OCT) has seen its share price jump by more than 20% this week after announcing that its CEO Dr John Lucas would be stepping down.
AFTER a month of relatively positive upwards trajectory for many European cannabis stocks, this week has seen a return to stagnation and decline, although a number of companies have managed to retain their price gains.
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to present an update on the development of its two lead compounds.
